Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

46P - [18F]2-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18FDG-PET/CT) in patients treated with immune checkpoint inhibitors (ICI) for microsatellite instability-high metastatic colorectal cancer (MSI mCRC)


09 Dec 2020


e-Poster Display Session


Staging and Imaging;  Tumour Immunology;  Immunotherapy

Tumour Site

Colon and Rectal Cancer


Thomas Pudlarz


Annals of Oncology (2020) 31 (suppl_7): S1428-S1440. 10.1016/annonc/annonc391


T. Pudlarz1, F. Montravers2, M. Garcia-Larnicol3, E. Kempf4, J. Bennouna5

Author affiliations

  • 1 Hôpital Saint-Antoine, Paris/FR
  • 2 Hôpital Tenon, Paris/FR
  • 3 Multidisciplinary Group in Oncology (GERCOR), Paris/FR
  • 4 Assistance Publique - Hopitaux De Paris, Paris/FR
  • 5 CHU du Nantes - Hôtel-Dieu, Nantes/FR

Abstract 46P


The interest of 18FDG-PET/CT to evaluate ICI efficacy is unclear. We aimed at investigating end-of-treatment 18FDG-PET/CT as well as its relationship with the occurrence of pathological complete response (pCR) for patients with MSI mCRC treated by ICI in resected residual lesions.


All patients from the multicenter NIPICOL phase II study (NCT03350126) with an end-of-treatment 18FDG-PET/CT were included (cohort A), as well as all ICI-treated MSI mCRC patients from Saint-Antoine hospital (Paris, France) who performed a 18FDG-PET/CT prior to the resection of a residual lesion (cohort B). Patients in NIPICOL study received nivolumab plus ipilimumab for 3 months, then nivolumab alone for a total of 1 year. We defined complete metabolic response (CMR) as the absence of lesions with a standard uptake value maximal (SUVmax) superior to the normal liver SUVmax.


Cohort A: 36 of 57 patients from the NIPICOL study had an end-of-treatment 18FDG-PET/CT with a median delay from the start of ICI of 12.5 month (95%CI = [12.1; 13.2]). All patients achieved a partial response (PR) or a stable disease (SD) according to RECIST1.1 criteria. CMR at the end of treatment was observed in 28/36 cases (78%). 19 of 22 patients with PR (86%) and 9 of 14 patients with SD (64%) had a CMR (p=0.22). With a median follow-up of 10.3 months after the 18FDG-PET/CT, one disese progression was reported, in a patient who did not achieve CMR at the end of treatment. Cohort B: among 10 patients who underwent a 18FDG-PET/CT prior to surgery of residual lesions, 6 had a pCR and 5 patients had a MCR (4 with pCR, 1 with residual tumor cells). Of note, one patient with pCR did not achived MCR. The positive and negative predictive values of 18FDG-PET/CT for pCR were 80.0% (95%CI 28.4-99.5) and 60.0% (95%CI 14.7-94.7), respectively (AUC 0.71).


MCR is frequent in patients with MSI mCRC treated with ICI but does not appear as a suitable tool to predict pCR.

Legal entity responsible for the study



Has not received any funding.


D. Tougeron: Honoraria (institution): BMS; Honoraria (institution): MSD oncology. T. Mazard: Research grant/Funding (institution): Roche; Honoraria (institution), Research grant/Funding (institution), Travel/Accommodation/Expenses: Amgen; Honoraria (institution): Sanofi; Honoraria (institution): BMS; Honoraria (institution): Sandoz. B. Chibaudel: Honoraria (institution): Pfizer; Honoraria (institution): Roche; Honoraria (institution): Sanofi; Honoraria (institution): Servier; Honoraria (institution): Bayer; Honoraria (institution): Beigine. M. Svrcek: Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Advisory/Consultancy: Astella; Advisory/Consultancy: MSD Oncology; Advisory/Consultancy: Sanofi; Travel/Accommodation/Expenses: Ventana/Roche. R. Cohen: Honoraria (self), Research grant/Funding (institution): Servier; Honoraria (self): MSD. T. Andre: Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: MSD Oncology; Travel/Accommodation/Expenses: Tesaro. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.